AI assistant
Sending…
Kezar Life Sciences, Inc. — Director's Dealing 2018
Jun 20, 2018
34845_dirs_2018-06-20_f8e33739-77cd-4f91-ad3e-9df37042008a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2018-06-20
Reporting Person: BERGER FRANKLIN M (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 53174 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | $ | Common Stock (262907) | Direct | ||
| Series B Convertible Preferred Stock | $ | Common Stock (197076) | Direct | ||
| Stock Option (Right to Buy) | $5.91 | 2028-04-15 | Common Stock (8896) | Direct |
Footnotes
F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock is convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2: One-hundred percent (100%) of the shares subject to the option shall vest January 1, 2019, subject to Reporting Person continuing to provide service through such date.
More from Kezar Life Sciences, Inc.
Delisting Announcement
2026
May 11
M&A Activity
2026
May 11
Interim / Quarterly Report
2026
May 11
Annual Report
2026
Apr 30
Legal Proceedings Report
2026
Apr 3
Merger & Acquisition
2026
Mar 30
M&A Activity
2026
Mar 30
Major Shareholding Notification
2026
Feb 9
Major Shareholding Notification
2025
Nov 14
Interim / Quarterly Report
2025
Nov 12